The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

August 16, 2019 • By Mary Choy, PharmD, BCGP, FASHP

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Jarun Ontakrai / shutterstock.com

Jarun Ontakrai / shutterstock.com

Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs used to treat patients with rheumatic disease. In Part 3 of this series, we discuss the 21 available options to treat rheumatoid arthritis (RA; see Table 1, opposite).

You Might Also Like
  • Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis
  • Rheumatology Drugs at a Glance, Part 2: Psoriasis
  • Drugs Studied for Use in Rheumatoid Arthritis, Weight Loss
Explore This Issue
August 2019
Also By This Author
  • Staying Positive & Learning from COVID-19: Q&A with Nilanjana Bose, MD, MBA

RA

RA is a common chronic autoimmune disorder characterized by the simultaneous inflammation of the synovium of multiple joints that frequently leads to joint destruction, deformity, and disability.1,2 The estimated prevalence of RA increases with age in both sexes and is greatest in patients aged 40–70 years old. Productivity loss at work is associated with personal, clinical and work-related factors for patients with RA.3 At-work productivity loss is also negatively associated with health-related quality of life, especially in the areas of mental health, physical role limitations and pain.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Most of the joint damage that leads to disability begins early in the course of the disease.4,5 A prompt diagnosis and a treat-to-target approach with tight monitoring and control can increase the likelihood of remission in RA patients.6 Strategies to achieve remission and/or low disease activity include initiating disease-modifying anti-rheumatic drug (DMARD) therapy early in the disease course to slow and prevent joint damage. Biologic therapies have been a significant advancement and improved the overall management of RA.

Nonpharmacologic therapies and preventative measures for patients with RA include patient education; psycho­social interventions; nutritional and dietary counseling; interventions to reduce the risks of cardiovascular disease, including smoking cessation and lipid control; screening for and treatment of osteoporosis; and immunizations to decrease the risk of infectious complications of immunosuppressive therapies.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The goals of treatment are to improve patients’ quality of life, reduce functional limitations, prevent joint damage and decrease disease complications. Treatment decisions should be made by the healthcare team and patients through a shared decision-making process, taking into account patients’ values and preferences, as well as their co-morbidities. It’s important to select the best therapeutic option for and with the patient to improve adherence and allow the patient to attain the highest level of satisfaction.

RA treatments can be expensive, and healthcare providers can help make treatment costs more manageable for patients. A number of financial assistance resources are available to patients, and patients can also contact the manufacturers to request co-pay assistance. Your staff can also explore patient assistance programs for those who do not have insurance (https://www.rheumatoidarthritis.org/resources).7

Depending on a patient’s healthcare coverage and the medication(s) they use, a specialty pharmacy may dispense the medications. Most specialty pharmacies have clinical pharmacists available who can help patients manage insurance issues, provide drug monitoring for adverse effects, effectiveness and adherence issues, and serve as a drug information resource.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

For additional information, review the ACR’s published RA guideline.1 The ACR anticipates publishing an updated guideline in late 2019/early 2020.

Pages: 1 2 3 4 5 6 7 8 9 10 | Single Page

Filed Under: Conditions, Drug Updates, Rheumatoid Arthritis Tagged With: abatacept, adalimumab, anakinra, baricitinib, Certolizumab Pegol, etanercept, Golimumab, infliximab, rituximab, sarilumab, tocilizumab, TofacitinibIssue: August 2019

You Might Also Like:
  • Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis
  • Rheumatology Drugs at a Glance, Part 2: Psoriasis
  • Drugs Studied for Use in Rheumatoid Arthritis, Weight Loss
  • Rheumatoid Arthritis Drugs May Cut Cardiovascular Risk

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)